Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2022 | Updates on treatment approaches for patients with BPDCN

Giovanni Marconi • 25 Oct 2022
SOHO Italy 2022
Blastic Plasmacytoid Dendritic Cell Neoplasm Rare Diseases Antibodies Pivekimab sunirine Tagraxofusp Venetoclax

Giovanni Marconi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses various treatment approaches for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Marconi highlights that while tagraxofusp is currently the preferred option for patients with BPDCN, preliminary clinical data indicates that the antibody-drug conjugate (ADC) pivekimab sunirine may benefit patients with relapsed/refractory (R/R) disease. This interview took place at the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Giovanni Marconi

1:36
Clinical trials evaluating novel agents in MDS: SELECT-MDS-1
Giovanni Marconi • 25 Oct 2022

Related Videos

3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
0:52
Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial • 7 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals